The discovery of genetic mapping led to a considerable expansion of medical data knowledge or ‘big data,’ which Foley partner Richard Kaufman suggests can be properly analyzed to improve drug discovery success and reduce the cost of developing a drug. He compares genetic mapping to an exquisite tailoring of one’s personal biology that holds the potential to make drugs developed using this data much more effective and ultimately may lead to better outcomes for patients.
People
Related News
July 24, 2025
In the News
Foley's Trial Team Featured Following Landmark Victory in Texas Trade Secret Case
Foley & Lardner LLP’s recent landmark appellate victory in a Texas trade secrets case is featured in the Texas Lawyer article, "Ruling Sets Precedent for Employment, Trade Secrets, Fiduciary Duty."
July 24, 2025
In the News
Gregory Husisian and David Simon on Tariff Evasion – 'Huge money at stake'
Foley & Lardner LLP partners Gregory Husisian and David Simon detailed the rise and risks of tariff evasion in the POLITICO article, "As Trump raises tariffs, companies find ways to cheat — and risk getting caught."
July 23, 2025
In the News
Aaron Maguregui on AI Scribes in Health Care – 'Technically, it's a third party listening'
Foley & Lardner LLP partner Aaron Maguregui shared insights on the growing applications for artificial intelligence across health care in the healthleaders article, “Is Your AI Scribe HIPAA-Compliant?“